Allogene Therapeutics (NASDAQ:ALLO) Issues Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) issued its earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06, Zacks reports.

Allogene Therapeutics Trading Down 4.4 %

Shares of NASDAQ:ALLO traded down $0.09 during midday trading on Monday, reaching $1.86. 1,215,595 shares of the company were exchanged, compared to its average volume of 3,040,015. The business's fifty day moving average is $1.94 and its two-hundred day moving average is $2.31. Allogene Therapeutics has a one year low of $1.32 and a one year high of $4.74. The stock has a market cap of $388.94 million, a PE ratio of -1.19 and a beta of 1.02.

Analyst Ratings Changes

Several research firms have recently weighed in on ALLO. Royal Bank of Canada reissued an "outperform" rating and set a $10.00 price objective on shares of Allogene Therapeutics in a report on Friday. Canaccord Genuity Group reissued a "buy" rating and set a $14.00 price objective on shares of Allogene Therapeutics in a report on Friday. Finally, Citizens Jmp raised shares of Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 price objective for the company in a report on Friday. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Allogene Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $9.40.

Remove Ads

Insider Buying and Selling

In other Allogene Therapeutics news, EVP Zachary Roberts sold 27,199 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total transaction of $48,414.22. Following the completion of the transaction, the executive vice president now owns 488,054 shares in the company, valued at $868,736.12. This trade represents a 5.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Timothy L. Moore sold 14,746 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the transaction, the insider now owns 250,713 shares of the company's stock, valued at $428,719.23. This trade represents a 5.55 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 52,710 shares of company stock worth $92,125. 24.30% of the stock is owned by insiders.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).